Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. - Wikidata - wikimedia - TriplyDB

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

http://www.wikidata.org/entity/Q34699088

about

Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines Improving Clinical Outcomes in Patients With Methicillin-Sensitive Staphylococcus aureus Bacteremia and Reported Penicillin Allergy Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges Universal immunity to influenza must outwit immune evasion H5N1 vaccines in humans Advancements in the development of subunit influenza vaccines Vaccination in the elderly Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates Cross-Allele Cytotoxic T Lymphocyte Responses against 2009 Pandemic H1N1 Influenza A Virus among HLA-A24 and HLA-A3 Supertype-Positive Individuals Inﬂuenza and Memory T Cells: How to Awake the Force Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA Universal influenza virus vaccines and therapeutic antibodies.Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases Vaccine-induced boosting of influenza virus-specific CD4 T cells in younger and aged humans MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection Vaccinia-based influenza vaccine overcomes previously induced immunodominance hierarchy for heterosubtypic protection.Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 influenza pandemic Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects.Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.Influenza vaccines: a moving interdisciplinary field.Adenoviral vectors as novel vaccines for influenza.Emerging influenza viruses and the prospect of a universal influenza virus vaccine.Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.Viral vector-based influenza vaccines.Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines Towards universal influenza vaccines?Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza.Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design Novel viral vectored vaccines for the prevention of influenza.Advances in the development of universal influenza vaccines.Pediatric influenza vaccination: understanding the T-cell response.Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses

P2860

Q26744622-773E416F-A0A6-43B9-A422-FF8028944538 Q26779453-6777479E-2302-489D-BBB4-EAC4AA7B2565 Q26783884-D9FEBF8B-8868-43F8-9A7A-4C28CC2A3518 Q26991896-9BAEBB05-7E80-488E-82CF-9E1F92623402 Q27000896-89D80E28-D1D8-4A54-887A-E73AC0921A8A Q27010100-470E1FC3-53B1-46CC-AB0F-B7E6B93A9F6D Q27022304-368399C5-081D-441C-BCCF-E87BCAA649BB Q27348520-36FCC019-06CB-4935-A559-222CCA3E4109 Q27673689-3D54CE7A-CF6B-4957-B02D-F4B5A8CC2AB6 Q28070255-946F53B9-B6F4-4CF2-9542-79F00A9F8E69 Q28727937-1C7CDC93-FA7B-4114-BEB6-87D9EB82BC5F Q30151337-78B36322-0643-41DD-8A92-3B44973F1F5B Q30209342-F670DF4A-B66F-4DCB-A7F5-CADE8CFF40BA Q30354893-4EE7A774-EDBC-45F2-A4C5-04877CD67C47 Q30358935-34774895-24B1-4F97-932E-278C9FA666D8 Q30361079-CF14C8F7-DEA4-468C-ADB0-8E05BE240D36 Q30362529-B4DF8C58-394F-436B-B379-8CD3A1BDEA4A Q30363471-8BDCE1FD-100D-4C77-B780-3F060F965065 Q30366119-F825E171-5468-47E6-9D92-9498802C4707 Q30366666-0A7B797A-C634-4424-A4AF-7F303FED132D Q30367695-417B279C-9168-47A3-B59C-58C6837740CA Q30370445-0E619A8D-273A-4BB3-B268-655C6881738E Q30372274-7DBD8881-40A0-41AD-BB27-E2423B329FCB Q30373077-7083EA0E-EC42-41B9-A6DE-1B39F369FDAE Q30373419-9EBEC217-43B6-4527-B8C4-8C92133CB952 Q30375380-927B1921-3BE0-4D6B-A5C4-8E0AC0283299 Q30390938-8FBC5F7B-3F8F-4697-B0F3-5859B31BBB11 Q30392456-6ED78178-2CBA-4287-8054-C4FC85F772C1 Q30396482-8ABDA9E0-58CC-4DDA-BB63-64F8BFD07512 Q30406748-6E94D6C1-DD1A-4FC2-8511-BE6433C6B67B Q30408295-204DA244-3434-43C8-9681-BCB2A601A368 Q30412892-65BF54DE-CF8F-40A2-A602-00E0CCE2EBBC Q30414543-6896AE1D-24E6-4673-948F-25E273EF428D Q30416502-1505FC51-DAB2-49EA-8918-3F1D807CA323 Q30418570-D54A42A5-1108-44AA-A22C-0405EF11E598 Q30421502-7A926547-B298-4A74-9F6D-2A4F93FAD6A9 Q30421553-81E84C66-0996-404A-B6F5-06F9B4FD1FD2 Q30425194-36D4D41F-FC69-4CAF-9157-CBEF74B94E97 Q30426730-EE77F61A-4F60-468E-9F50-5C0386A35291 Q30427591-910D8C2F-8D6F-4AC4-AF7F-283C94AE39E7

P2860

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

http://www.wikidata.org/entity/Q34699088

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@ast

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@en

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@nl

type

label

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@ast

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@en

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@nl

prefLabel

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@ast

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@en

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@nl

P1433

Q34699088-0DEB065F-98BA-4157-B06C-9F4CD3EB5806

P1476

Q34699088-CA5C03B2-B1DB-4F95-8E73-56F56FB9759A

P2093

Q34699088-1DEDA2A1-EB6C-44E4-9A7A-89A095188E0E

Q34699088-3D81F63F-2F40-4296-8CEA-889F71FB7C7F

Q34699088-5A8E11BC-B15C-4153-A9D5-790CAE7FC6D8

Q34699088-AA728942-DF70-49D9-9EDE-49F123A995B6

Q34699088-D08B7BF3-2116-48A0-A3B4-D34A7BA38482

P2860

Q34699088-01EB7A06-0813-4B65-AB05-F5CDB6AA81BC

Q34699088-0AC1CFE7-4D5F-468E-B54D-6D7537C6C1C9

Q34699088-0FEA467B-EBE9-4C61-8C6A-D48059734F43

Q34699088-19276B5F-92BD-4A4A-8281-206F04C1FD68

Q34699088-20D1CBA3-F76A-4A1C-94D6-C4DB333A6E79

Q34699088-4D81A101-3D01-44EC-A30E-5D1B85FE5339

Q34699088-566230D9-FE2F-48D0-A33C-8FD34419E015

Q34699088-5A074818-9318-4F62-911D-2F297541821C

Q34699088-5DC4BA88-F68D-40C6-9708-8866047B18A5

Q34699088-7280B17E-817F-4702-81D0-DBEF1B5FE5B8

P304

Q34699088-9B185B61-5713-4ABC-B6A9-84F0C332095F

P31

Q34699088-61AF2CCE-86D4-4047-99B4-85BA62288F4A

P356

Q34699088-2E10A336-58E5-4611-825E-52C118B2503A

P407

Q34699088-061477BF-7C50-457F-B5C6-7CC7522AF337

P433

Q34699088-4B665E98-4E7D-4AFD-878D-AFA72F738313

P478

Q34699088-D261FBFB-5DF5-40EE-8AFF-8AF189555670

P50

Q34699088-388DC6E6-17A8-4AEE-98A9-75EA9D72C7CD

Q34699088-433B19A5-E7F6-4BDB-B5D2-09A04D7F723C

Q34699088-782755FA-F249-4A7A-8B14-1A18E4765C70

Q34699088-8D8971AA-57B1-4A5E-AE76-4FA11C18E261

Q34699088-8F4B81F5-BE0D-4019-BB24-9A8A77C9B0FB

Q34699088-A1D72A48-C279-4446-817A-828F941D7B40

Q34699088-F0A561C7-582F-4D0D-83DA-60A347F562D5

P577

Q34699088-74DC1EE5-0E9F-4FE1-AEFE-D78E5C9143BE

P5875

Q34699088-B06F1884-454B-46A2-8750-9C783DBA0297

P698

Q34699088-08E2198A-B8B2-4E01-BFB3-7DC8FD22290C

P932

Q34699088-C1616020-8D5E-4ED6-A6CD-AEF2E01E1BBB

P356

P1433

Clinical Infectious Diseases

P1476

Potent CD8+ T-cell immunogenic ...... nfluenza A vaccine, MVA-NP+M1.

@en

P2093

Anita Milicic

http://www.w3.org/2001/XMLSchema#string

Hazel C Poyntz

http://www.w3.org/2001/XMLSchema#string

Lenias Hwenda

http://www.w3.org/2001/XMLSchema#string

Matthew Hamill

http://www.w3.org/2001/XMLSchema#string

Tamara K Berthoud

http://www.w3.org/2001/XMLSchema#string

P2860

Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.

Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

P304

1-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIQ015

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Adrian V. S. Hill

Sarah Catherine Gilbert

Katharine A Collins

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49674378

http://www.w3.org/2001/XMLSchema#string

P698

21148512

http://www.w3.org/2001/XMLSchema#string

P932

3060888

http://www.w3.org/2001/XMLSchema#string